



Issuer Ascelia Pharma AB

Holder

Sunstone LSV General Partner II ApS, acting in its capacity as General Partner of Sunstone Life Science Ventures Fund II K/S

Instrument

Instrument Ordinary shares SE0010573113

Before the transaction

Shares Data not given*

Voting rights Data not given*

Transaction

Reason for major shareholding notification Corporate action

Date 30/04/2021

Limit for number of shares 15 %

Limit for number of votes 15 %

After the transaction

Quantity

Shares 4,778,129

Directly held voting rights 0

Indirectly held voting rights 4,778,129

Percentage

Directly held shares 13.81903 %

Directly held voting rights 0 %

Indirectly held voting rights 14.15361 %

Resulting distribution of total holdings

| | Percentage of voting rights: | Number of underlying shares: |
|--------|------------------------------|------------------------------|
| Shares | 14.15361 % | 4,778,129 |

Instruments - FITA Ch. 4, section 2, first paragraph, line 2

Instruments - FITA Ch. 4, section 2, first paragraph, line 3

- Physically settled

- Cash settled

Total 14.15361 % 4,778,129

Chain of controlling companies

Voting rights % Voting rights Company

4,778,129 14.15361 Sunstone Life Science Ventures Fund II K/S

Group total holdings

Voting rights 4,778,129

Percentage of voting rights 14.15361

Notes (other relevant informations according to law)

Notification is made due to increased number of shares and votes in Ascelia Pharma AB announced on April 30th, 2021, resulting in the holder falling below the 15 % equity and vote threshold.

Published

05/05/2021 09:30

*Source of information has chosen not to submit the data

[CLOSE](#) [PRINT](#)